Patent Landscape Analysis: US Patent 11,484,527 (Claims for IBS-D Method of Reducing Abdominal Pain and Diarrhea at 100 mg Twice Daily With Food)
US Patent 11,484,527 is a US method-of-treatment patent centered on an adult human with irritable bowel syndrome with diarrhea (IBS-D), using a specified small-molecule benzoic acid derivative dosed at 100 mg twice daily with food, and claiming efficacy endpoints tied to daily worst abdominal pain (WAP) and Bristol Stool Scale (BSS). The claim set creates a litigation-relevant fence around (i) the exact dosing regimen and (ii) response-based achievement thresholds for pain and stool consistency, with dependent claims adding specific performance metrics (20%/30% WAP improvement; BSS ranges).
This analysis maps claim scope, likely infringement theory boundaries, claim construction pressure points, and the US competitive patent landscape implications for generic or branded entrants pursuing an IBS-D product.
What does US 11,484,527 claim, and what is the method-of-use scope?
Core independent claim (Claim 1)
- Patient population: adult human patient suffering from irritable bowel syndrome with diarrhea (IBS-D).
- Intervention: orally administer to the adult patient 100 mg of a defined chemical compound:
- 5-({[(2S)-2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
- Dose regimen: twice daily
- Administration condition: with food
- Claim purpose: “reducing the frequency of abdominal pain and diarrhea”
Dependent claim add-ons
- Claim 2: at least 20% improvement in daily worst abdominal pain (WAP) vs baseline.
- Claim 3: at least 30% improvement in daily WAP vs baseline.
- Claim 4: stool consistency improved such that BSS is between 2 and 5.
- Claim 5: stool consistency improved such that BSS is less than 5.
- Claim 6: combination response: (a) ≥30% WAP improvement and (b) BSS <5.
Practical scope summary
- The patent is not a composition patent on a formulation alone; it is a method-of-use patent keyed to dosing instructions and clinically measured outcomes.
- The claim requires both the treatment setting (IBS-D adult) and the specific dosing and administration context (100 mg BID with food).
- The dependent claims add threshold response elements that can narrow infringement, but also create multiple infringement paths if the accused product’s labeling and real-world use meet the thresholds.
How specific is the claimed active ingredient and does the chemistry constrain infringement?
Chemical definition appears to be the key scope anchor
Claim 1 specifies a single defined molecule by structural naming. That structure-level specificity can materially constrain infringement because:
- A different compound, even if pharmacologically related for IBS-D, likely falls outside literal scope unless it is proven to be an equivalent under the doctrine of equivalents.
- For generic entrants, the active ingredient must match the claimed molecule. If the generic targets a different salt, polymorph, or solvated form, infringement often still remains on the active moiety if the claims cover the compound generally. But if the claims are interpreted as covering the exact chemical entity as named, applicants can still argue differences in identity outside literal coverage.
Key claim-construction friction points
- Whether the named compound definition is interpreted as including salts and hydrates of the same base structure (common in pharma patent practice for method claims tied to “administering 100 mg of” a named entity).
- Whether the compound is present as a specific stereochemical configuration (the name includes (2S) and (1S)). If the drug uses a different stereoisomeric composition, literal infringement risk can increase for developers.
What dosing and “with food” elements narrow claim coverage?
Dose and regimen
- 100 mg twice daily is explicit.
- Twice daily can still be satisfied by some flexible dosing schedules if courts interpret “twice daily” as two administrations per day in a general sense, but the numeric regimen will be enforced as part of literal claim scope.
Administration condition: “with food”
- This is a second tight boundary.
- If an accused product’s prescribing information or instructions emphasize dosing without food, infringement becomes less likely unless physicians instruct or patients follow “with food” conditions in practice.
- For Paragraph IV cases, the most common hinge is whether the proposed generic label and FDA-approved instructions align with “with food.” If label does not require “with food,” plaintiffs may still argue induced infringement via off-label or real-world use, but that raises evidentiary complexity.
Infringement design-around levers
- A developer can attempt to (i) change dose strength or regimen and (ii) remove “with food” from labeling. That may avoid literal infringement but must also consider method-of-use variants and dependent claims that could be asserted in separate theories.
What do the response-based dependent claims (WAP and BSS thresholds) change for infringement?
Claim 2 and 3: WAP improvement thresholds
- Claim 2 requires ≥20% improvement in daily WAP vs baseline.
- Claim 3 requires ≥30% improvement.
Claim 4 and 5: BSS range
- Claim 4 requires BSS between 2 and 5.
- Claim 5 requires BSS <5.
Claim 6: dual endpoint
- Requires ≥30% WAP improvement and BSS <5.
Legal and evidentiary implications
- Response-based elements can create “real world outcome” proof demands. A plaintiff typically needs:
- Trial evidence matching these endpoints, or
- Labeling language that implicitly promises these thresholds, or
- Post-marketing/claims data demonstrating that patients treated under the accused regimen meet those thresholds.
Business implication
- Even if generic infringement of Claim 1 is contested on dosing and “with food,” the dependent claims can be powerful settlement leverage if the brand’s pivotal data and label already map onto the specific thresholds (20% and 30% WAP; BSS <5).
Where are the most likely claim scope challenges and construction disputes?
1) Definition of “frequency of abdominal pain and diarrhea”
Claim 1 uses “reducing the frequency” but the dependent claims reference daily worst abdominal pain (WAP) percent improvement, not explicit frequency counts. This can create argument space:
- Plaintiff will argue WAP reduction is a proxy for reduced frequency/severity consistent with IBS-D symptom burden.
- Defendant will argue mismatch between “frequency” language and measurement method.
2) “Daily worst abdominal pain (WAP) score” measurement
- If multiple trials or measurement regimes exist (e.g., different baselines, diary compliance rules), construction issues can arise as to:
- what constitutes the “daily worst” point,
- the timing window for baseline and follow-up,
- handling of missing diary entries.
3) BSS scoring methodology
- BSS is standardized but:
- endpoint timing matters (e.g., average over week vs single-day measurement),
- the claimed ranges could be satisfied or missed depending on analysis approach.
4) “With food” operational meaning
- Courts and experts may treat “with food” as a categorical dosing instruction, but defendants can argue that if “food” is not required in the approved product instructions, literal method conditions are not met.
How long does US 11,484,527 remain in force, and when does exclusivity end?
No complete patent-file data provided
The user input includes the claims but not the patent’s filing date, priority date, application number, or expiration mechanics (including PTA). Without those facts, any specific expiration date would be speculative.
What can be stated from claim structure
- The patent is a US utility method-of-treatment claim set. Its effective lifetime is governed by US utility term rules (priority filing date plus 20 years, subject to adjustments), but the specific “lose exclusivity” date depends on priority and prosecution history.
(This section is intentionally not dated to avoid fabricated expiration detail.)
What other patents usually co-exist with a method claim like 11,484,527 in IBS-D?
Even without identifying related family members from file history, IBS-D patent estates commonly cluster around:
- Composition of matter (the active molecule and related salts/polymorphs).
- Dosing regimen patents (dose range, twice daily, administration conditions).
- Method-of-treatment patents (IBS-D symptom endpoints: pain, stool consistency, urgency).
- Patient phenotype patents (subgroups: inadequate responders, stool frequency strata).
- Combination therapy patents (add-on agents).
- Formulation/manufacturing patents (release profile, bioavailability enhancement).
How 11,484,527 likely interacts
- This patent’s specificity suggests it may be asserted as a later “clinical outcome” fence around label-like dosing and endpoints. In practice, method patents often accompany earlier chemical and formulation patents, creating a layered estate.
How strong is the patent estate around this claim set (and what makes it enforceable)?
Strength drivers
- Tight regimen lock: 100 mg BID with food is specific.
- Clinical endpoints: WAP and BSS thresholds are measurable and commonly used in IBS-D trials.
- Dual endpoint claim (Claim 6): narrows to a combined efficacy achievement, useful for asserting strong label congruence.
Potential weakness drivers
- Narrowing by conditions: if accused use differs on “with food” or dose regimen, literal infringement risk falls.
- Outcome variability: response-based thresholds can be disputed if different trial endpoints, statistical definitions, or patient populations apply.
Enforcement leverage
- Method claims with well-defined endpoints are often easier to enforce when:
- the brand label mirrors the trial design and endpoints, and
- generic label carve-outs or omission of “with food” do not prevent physicians from following the method.
What generic entry risks exist for an IBS-D product that uses the same active ingredient?
If the generic product uses the same molecule
- Literal infringement risk of Claim 1 rises if the generic is prescribed as 100 mg twice daily with food for adult IBS-D and is used to reduce abdominal pain and diarrhea.
- Claim 2-6 add endpoint thresholds, which can be litigated based on clinical data congruent with the brand’s trial framework.
If the generic changes the regimen
- A switch to a different total daily dose, a once-daily approach, or a dosing instruction without food can reduce literal coverage.
If the generic changes labeling
- For method-of-use patents, labeling matters, especially for induced infringement arguments tied to “instructions” or “promote use.”
- Manufacturers can attempt to steer prescribers away from “with food” language.
Settlement pattern likelihood
- If the generic is otherwise bioequivalent and the main remaining dispute is method-of-use, settlements often focus on:
- carve-outs in labeling,
- timing of launch,
- permitted indications or dosing instructions.
What patent litigation hooks do the dependent claims create?
The dependent claims (2-6) create multiple potential “assertion nodes”:
- A plaintiff can choose to plead the independent method first (Claim 1), then add response elements as optional additional counts (2-6).
- Defendants may attack:
- whether the accused product meets “with food,” and
- whether real-world outcomes reach WAP and BSS thresholds.
Key litigation friction
- Plaintiffs need to link the specific endpoint thresholds to the accused regimen and patient population.
- Defendants can counter with differences in:
- patient baseline severity,
- trial design and diary scoring,
- outcome assessment windows.
What is the Orange Book status of US 11,484,527, and which NDAs/labels likely map to the claimed dosing?
No NDA number, drug name, or Orange Book listing details were provided in the user input. Without the specific FDA product identity and Orange Book record, a precise status mapping is not possible.
(This section is intentionally omitted to avoid incorrect Orange Book associations.)
How does 11,484,527 compare with other IBS-D method patents?
Positioning
- 11,484,527’s claim set is a typical “clinical outcome method” format: defined dosing + defined endpoints.
- Compared with broader regimen patents (dose ranges, flexible administration), it is narrower.
- Compared with combination therapy patents, it is single-agent.
Competitive impact
- Narrower method claims reduce the number of design-around options to those that touch dosing, food condition, or measurement/endpoint mapping.
- If a competitor uses the same dosing instruction set and targets the same endpoints, this patent is more directly threatening than broader patents would be.
Where is geographic coverage relevant, and is this US-only?
This is a US patent. The scope and enforcement impact depend on:
- US filing date and term,
- whether corresponding family members exist in other jurisdictions.
No family map or foreign equivalents were provided. A cross-jurisdiction assessment is not possible from the provided claim text alone.
Claim-by-claim scope table (practical infringement and proof focus)
| Claim |
Added requirement |
What it narrows |
Typical proof focus in litigation |
| 1 |
IBS-D adult; administer 100 mg; twice daily; with food; method to reduce abdominal pain and diarrhea |
Drug identity + dosing + administration condition + patient population |
Labeling/instructions, real-world use evidence, trial regimen matching, clinical endpoint mapping |
| 2 |
≥20% improvement in daily worst WAP vs baseline |
Endpoint achievement |
Trial data or evidence showing threshold met |
| 3 |
≥30% improvement in daily WAP vs baseline |
Stronger endpoint |
Same as above, higher bar |
| 4 |
BSS improved to 2–5 |
Stool consistency range |
Diary or stool assessment data |
| 5 |
BSS improved to <5 |
Broader than claim 4 but still strict |
Evidence of <5 classification |
| 6 |
≥30% WAP improvement and BSS <5 |
Dual endpoint |
Evidence that both thresholds simultaneously met |
Key Takeaways
- US 11,484,527 claims a method-of-treatment for IBS-D adult patients using a defined stereochemically specified benzoic acid derivative at 100 mg twice daily with food.
- The independent claim is tightly constrained by drug identity, 100 mg BID regimen, and the “with food” condition, making labeling and real-world dosing behavior central to infringement analysis.
- Dependent claims add measurable thresholds: WAP improvement (≥20% or ≥30%) and BSS outcomes (2–5 or <5), culminating in a dual endpoint claim (≥30% WAP + BSS <5) that can heighten litigation leverage when trial endpoints match label language.
- The largest practical design-around levers are changing dose regimen, removing “with food” from labeling, or using a different active ingredient; proof disputes will likely focus on endpoint methodology and whether the “with food” condition is met.
FAQs
1) What happens if a competitor uses the same molecule but different dosing frequency (e.g., once daily)?
Claim 1 requires twice daily; changing administration frequency creates a direct mismatch to literal scope, shifting infringement analysis to doctrine of equivalents and evidence of claim construction.
2) Can a generic avoid infringement by omitting “with food” from its prescribing information?
Avoiding literal infringement becomes more feasible if the approved instructions do not require food. The remaining risk is induced infringement or real-world practice evidence showing the patented method is nonetheless followed.
3) How do WAP and BSS endpoint thresholds affect litigation strategy?
They create additional counts with specific performance burdens. Plaintiffs can emphasize endpoint-congruent trial evidence; defendants can challenge how WAP and BSS are measured, timed, and analyzed.
4) Does the patent cover any IBS-D diarrhea patient or only those meeting specific clinical criteria?
From the claims provided, it covers adult human patients suffering from IBS-D; no additional phenotype thresholds appear in the claim text itself.
5) If the accused product achieves symptom improvements, does that automatically establish infringement?
No. Even if outcomes improve, infringement requires meeting all method conditions of Claim 1 (including the dosing regimen and “with food”). Dependent claims additionally require meeting specific threshold outcomes.
References (APA)
- User-provided claim text for US Drug Patent 11,484,527 (method claims 1-6).
